Angiotensin II-receptor antagonist Losartan does not prevent nitroglycerin tolerance in patients with coronary artery disease

Cardiovascular Drugs and Therapy

Volumn 18, Issue 5, 2004, Pages 363-370

  Longobardi, Giancarlo ^a,d   Ferrara, Nicola ^a,b   Leosco, Dario ^c   Abete, Pasquale ^c   Furgi, Giuseppe ^a   Cacciatore, Francesco ^a   Corbi, Graziamaria ^a   Pescatore, Raffaella ^a   Rengo, Franco ^a,c  

^a IRCCS   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d IRCCS   (Italy)

Author keywords

AT1 antagonist; Losartan; Nitrate tolerance

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; LOSARTAN; PLACEBO;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; DRUG TOLERANCE; EXERCISE TEST; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; SYSTOLIC BLOOD PRESSURE; TIME;

ADMINISTRATION, CUTANEOUS; ANGINA PECTORIS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; NITROGLYCERIN; VASODILATOR AGENTS;

EID: 17644386878     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-5060-1     Document Type: Article

References (42)

1. Thadani U, Fung H-L, Darke AG, et al. Oral isosorbide dinitrate in angina pectoris: Comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol 1982;49:411-419.
2. Dalal JJ, Yao L, Parker JO. Nitrate tolerance: Influence of isosorbide dinitrate on the hemodynamic and antianginal effects of nitroglycerin. J Am Coll Cardiol 1983;2:115-120.
3. Thadani U, Manyari D, Parker JO, et al. Tolerance to the circulatory effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation 1980;61:526-535.
4. Parker JO, VanKoughnett KA, Fung HL. Transdermal isosorbide dinitrate in angina pectoris: Effect of acute and sustained therapy. Am J Cardiol 1984;54:8-13.
5. Parker JO, Fung HL. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984;54:471-476.
6. Parker JO, Vankoughnett KA, Farrell B. Comparison of buccal nitroglycerin and oral isosorbide dinitrate for nitrate tolerance in stable angina pectoris. Am J Cardiol 1985;56:724-728.
7. Thadani U, Hamilton SF, Olson E, et al. Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol 1987;59:756-762.
8. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
9. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-931.
10. Parker JD, Farrell B, Fenton T, et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-2345.
11. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184:709-715.
12. Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation 2000;102:2810-2815.
13. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187-194.
14. Munzel T, Giaid A, Kurz S, et al. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA 1995;92:5244-5248.
15. Katz RJ, Levy WS, Buff L, et al. Prevention of nitrate tolerance with angiotension converting enzyme inhibitors. Circulation 1991;83:1271-1277.
16. Munzel T, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 1996;93:2052-2058.
17. Dakak N, Makhoul N, Flugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:608-613.
18. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counter-regulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993;21:1445-1453.
19. ISIS4 Collaborative Group. International Study of Infarct Survival 4 (ISIS4): A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulfate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
20. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: The GISSI-3 trial. J Am Coll Cardiol 1996;27:337-344.
21. Kurz S, Hink U, Nickenig G, et al. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 1999;99:3181-3187.
22. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation 1995;91:1368-1374.
23. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-795.
24. Frame MD, Fox RJ, Kim D, et al. Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II. Am J Physiol Heart Circ Physiol 2002;282:H2377-H2385.
25. Cotter G, Metzkor-Cotter E, Kaluski E, et al. Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris. Am J Cardiol 1998;82:1024-1029.
26. Milone SD, Azevedo ER, Forster C, et al. The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. J Cardiovasc Harmacol 1999;34:645-650.
27. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-1342.
28. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-713.
29. Hirai N, Kawano H, Yasue H, Shimomura H, Miyamoto S, Soejima H, Kajiwara I, Sakamoto T, Yoshimura M, Nakamura H, Yodoi J, Ogawa H. Attenuation of nitrate tolerance and oxidative stress by an angiotensin II receptor blocker in patients with coronary spastic angina. Circulation 2003;108(12):1446-1450.
30. Ertl G, Kloner RA, Alexander RW, et al. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-48.
31. Schneider CA, Voth E, Moka D, et al. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: A study using [15O] water dobutamine stress positron emission tomography. J Am Coll Cardiol 1999;34:1005-1011.
32. Longobardi G, Ferrara N, Leosco D, et al. Failure of protective effect of captopril and enalapril on exercise and dipyridamole-induced myocardial ischemia. Am J Cardiol 1995;76:255-258.
33. Pepine CJ, Rouleau JL, Annis K, et al. QUASAR Study Group. Effects of angiotensin-converting enzyme inhibition on transient ischemia: The Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol 2003;42(12):2049-2059.
34. Wang EQ, Lee WI, Brazeau D, et al. cDNA microarray analysis of vascular gene expression after nitric oxide donor infusions in rats: Implications for nitrate tolerance mechanisms. AAPS PharmSci 2002;4:E10.
35. Gori T, Parker JD. Nitrate tolerance: A unifying hypothesis. Circulation 2002;106:2510-2513.
36. Parker JO, Parker JD, Caldwell RW, et al. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol 2002;39:1199-1203.
37. McVeigh GE, Hamilton P, Wilson M, et al. Platelet nitric oxide and superoxide release during the development of nitrate tolerance: Effect of supplemental ascorbate. Circulation 2002;106:208-213.
38. Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: A human in vivo study. Circulation 2001;104:1119-1123.
39. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. J Cardiol 1998;31:173-181.
40. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 2002;99:8306-8311.
41. Sudhir K, MacGregor JS, Gupta M, et al. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies. Circulation 1993;87:931-938.
42. Akinboboye OO, Chou RL, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: A comparison of lisinopril and losartan. J Am Coll Cardiol 2002;40:703-709.